{"filings":[{"id":815402,"accession_number":"0001493152-26-026965","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-06-03T11:00:17+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.","Sam Lee becomes President and Chief Scientific Officer; Jim Martin remains CFO.","Sapirstein has led 23 product launches and served as CEO of Contravir and Tobira Therapeutics.","Company plans to appoint Sapirstein to the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":650036,"accession_number":"0001493152-26-025172","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-05-26T12:30:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.","Company expanding platform from CDI-988 (Phase 1b norovirus) to hantavirus, bunyavirus, influenza.","No approved treatments or vaccines for hantaviruses; Andes strain linked to recent cruise ship outbreak with 3 deaths.","Plans to evaluate activity against Andes hantavirus replication enzyme and explore partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92715,"accession_number":"0001493152-26-020586","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma presents CDI-988 data at ICAR 2026; Phase 1b norovirus study fully enrolled in stage 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.","Phase 1b study fully enrolled first cohort to assess infectivity of GII.2 Snow Mountain Virus inoculum.","CDI-988 is first oral direct-acting antiviral for norovirus; targets conserved 3CL protease across strains.","FDA Fast Track designation granted for CDI-988 for norovirus treatment and prophylaxis.","No approved treatments or vaccines for norovirus; $60 billion annual economic burden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92714,"accession_number":"0001493152-26-014819","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.","CDI-988 is first oral antiviral candidate for both treatment and prophylaxis of norovirus infection.","Phase 1b double-blind challenge study (NCT07198139) ongoing at Emory University in up to 40 adults.","Norovirus causes ~685M global infections/year with ~$60B worldwide economic impact.","Fast Track enables rolling NDA review and potential Priority Review; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103769,"accession_number":"0001493152-26-013837","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma reports 2025 net loss of $8.8M ($0.78/sh); cash $7.7M; norovirus challenge study underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.","Unrestricted cash $7.7M at Dec 31, 2025 vs $9.9M a year earlier; working capital $5.9M.","Phase 1b norovirus challenge study of CDI-988 underway at Emory; first cohort evaluating GII.2 strain.","CDI-988 is first oral antiviral candidate for norovirus; no approved treatments/vaccines exist; $60B global burden.","Influenza CC-42344 Phase 2a completed; efficacy not reported due to trial conduct; plans for additional Phase 2a study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103768,"accession_number":"0001493152-26-010071","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cocrystal Pharma board member Dr. Anthony Japour passes away on March 10, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Anthony Japour, a member of Cocrystal Pharma's board of directors, died on March 10, 2026.","The company reported the sad event in a Form 8-K filed March 13, 2026.","No replacement or further board changes announced as of the filing date.","Dr. Japour's passing reduces the board size; no other details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103767,"accession_number":"0001493152-26-009309","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.","CDI-988 is a direct-acting oral antiviral targeting 3CL protease; no approved norovirus treatments or vaccines exist.","Study to enroll up to 40 healthy subjects; primary endpoint is reduction of clinical symptoms vs placebo.","CDI-988 previously showed favorable safety in Phase 1; global norovirus economic burden estimated at $60B annually.","FDA issued Study May Proceed Letter in Sep 2025; Emory IRB approval obtained Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103766,"accession_number":"0001493152-26-007430","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.","Company to present Phase 1b challenge study data at ICAR 2026 in Prague (Apr 27-May 1, 2026).","No approved antiviral therapies or vaccines for norovirus; estimated $10.6B annual US economic burden.","CDI-988 is a pan-viral protease inhibitor also targeting coronaviruses, developed using proprietary structure-based platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103765,"accession_number":"0001493152-26-002422","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.","Vesting: 50% on Jan 9, 2027; remaining 50% in 8 quarterly installments starting Mar 31, 2027.","Dr. Roger Kornberg receives 24,615 options (plus $50,000 cash award for SAB chair); James Martin and Sam Lee each receive 49,229.","Directors (excluding executives) each receive 16,410 options; consultant receives 40,000 options.","Options have 10-year term, exercise price set at Jan 8, 2026 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120024,"accession_number":"0001493152-25-028296","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma gets IRB approval for Phase 1b norovirus challenge study with CDI-988; enrollment starts Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.","Enrollment expected to begin Q1 2026; study involves up to 40 healthy subjects ages 18-49.","CDI-988 is first oral broad-spectrum antiviral for norovirus; no approved treatments or vaccines currently exist.","Study is randomized, double-blind, placebo-controlled; primary endpoint is reduction in clinical symptoms.","Follows prior FDA clearance of IND and favorable Phase 1 safety data from August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120023,"accession_number":"0001493152-25-025568","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma to present at NobleCon 21 on Dec 3, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CFO/co-CEO James Martin to give Company overview and clinical progress update.","Presentation at Noble Capital Markets' 21st Emerging Growth Equity Conference on Dec 3, 2025 at 10:00 AM ET.","Conference held at Florida Atlantic University in Boca Raton, Florida.","Webcast will be archived for 90 days on Cocrystal's website starting Dec 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120022,"accession_number":"0001493152-25-022603","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.","Granted NIH SBIR award of $500,000 for influenza A/B replication inhibitor program.","Q3 2025 R&D expenses $954,000 vs $3.2M in Q3 2024; net loss $2.0M ($0.19 per share) vs $4.9M ($0.49 per share) year-over-year.","Raised $4.7M in registered direct offering in September 2025 and $1.03M in private placement in October 2025.","CC-42344 Phase 2a study completed; showed favorable safety, no SAEs; efficacy not reported due to trial conduct issues."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120021,"accession_number":"0001493152-25-020143","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma raises $1.03M in private placement with four insider investors at $1.39/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 739,426 units (1 share + 2 warrants) at $1.39/unit for $1.03M to four accredited insider purchasers.","Warrants exercisable at $1.24/share for 27 months; potential additional $1.83M if fully exercised.","Insiders include Directors Phillip Frost, Fred Hassan, Richard Pfenniger, and co-CEO/CFO James Martin.","Proceeds to support clinical antiviral development programs and general working capital.","Offering exempt under Section 4(a)(2) and Regulation D; no registration rights granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120020,"accession_number":"0001493152-25-019706","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.","Approximately $500,000 in non-dilutive funding; Phase I award to assess scientific and commercial potential.","Funds will be used to characterize lead candidate molecules inhibiting the influenza polymerase complex.","Successful Phase I completion may qualify Cocrystal to apply for a larger Phase II award.","Company continues to pursue additional non-dilutive government and military funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136587,"accession_number":"0001493152-25-013495","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.","Warrants issued to purchase 5,529,420 shares at $1.50, potential additional $8.3M.","Net proceeds for working capital and antiviral drug development.","H.C. Wainwright acted as placement agent; warrants expire 24 months after resale registration effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136586,"accession_number":"0001641172-25-027247","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma showcases CDI-988 at calicivirus conference, notes FDA clearance for Phase 1b challenge study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.","CDI-988 is a first oral antiviral candidate for norovirus, with broad-spectrum activity against GII.4 and GII.17.","Phase 1 showed favorable safety and tolerability, with no serious adverse events.","FDA cleared a Phase 1b human challenge study for norovirus prophylaxis/treatment; expected start before end of 2025.","CDI-988 targets a conserved region in 3CL viral proteases, designed with Cocrystal's proprietary structure-based platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136585,"accession_number":"0001641172-25-027246","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma announces up to $13M registered direct offering at $1.70/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$4.7M upfront from sale of 2,764,710 shares at $1.70; closing expected Sep 15, 2025.","Concurrent private placement of warrants to purchase up to 5,529,420 shares at $1.50, exercisable on issuance, 24-month term.","Potential additional gross proceeds of ~$8.3M if warrants fully exercised on cash basis.","H.C. Wainwright & Co. acting as exclusive placement agent.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136584,"accession_number":"0001641172-25-023727","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.","Cash and equivalents $4.8M as of June 30, 2025, down from $9.9M at Dec 31, 2024; working capital $4.9M.","Favorable CDI-988 Phase 1 safety/tolerability data for all doses including 1200 mg; Phase 1b norovirus challenge study planned in 2025.","CC-42344 Phase 2a challenge study extended due to low influenza infection rates; compound active against H5N1 avian strain.","R&D expenses $1.1M in Q2 2025 vs $4.3M in Q2 2024; G&A $1.0M vs $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136583,"accession_number":"0001641172-25-022153","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.","Treatment-emergent AEs in SAD: 28% (10/36) CDI-988 vs 40% (4/10) placebo; MAD: 53% (19/36) vs 92% (11/12).","Company expects to initiate Phase 1b challenge study in norovirus-infected healthy subjects later in 2025.","Headache most common AE; no clinically relevant ECG changes or pathology results reported.","CDI-988 targets 3CL viral proteases; potential prophylaxis/treatment for norovirus and coronaviruses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136582,"accession_number":"0001641172-25-018600","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.","Oral presentation by co-CEO Sam Lee on Sept 11, 2025 at the 9th International Calicivirus Conference in Banff.","Phase 1 study completed evaluating safety, tolerability, pharmacokinetics, and food effect in healthy adults.","No approved vaccine or antiviral exists for norovirus; CDI-988 targets a conserved region of 3CL protease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136581,"accession_number":"0001641172-25-017370","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cocrystal Pharma shareholders elect directors, ratify auditor, approve 2025 equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected six directors: Kornberg (4,386,691 for), Frost (4,344,444 for), Hassan (4,440,602 for), Japour, Pfenniger, Rubin.","Ratified Weinberg & Company as independent auditor for FY2025 (6,166,964 for, 452,222 against).","Approved 2025 Equity Incentive Plan (3,764,418 for, 714,962 against).","Adjournment proposal moot due to sufficient votes on other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153784,"accession_number":"0001641172-25-015571","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cocrystal Pharma reduces stockholder meeting quorum to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved bylaw amendment on June 17, 2025 reducing quorum to one-third of voting power.","Quorum now requires one-third of outstanding shares entitled to vote, down from majority.","Amendment effective immediately; full text filed as Exhibit 3.1.","No other changes to bylaws or fiscal year were made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153783,"accession_number":"0001641172-25-013776","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.","Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment; no approved antivirals or vaccines for norovirus currently exist.","President and co-CEO Sam Lee, PhD, will discuss Phase 1 safety, tolerability, and pharmacokinetics results at the conference.","CDI-988 targets a highly conserved region in 3CL viral proteases, potentially halting infection early regardless of viral strain or mutation.","Norovirus spreads rapidly in confined spaces like military settings, posing a threat to operational effectiveness and economic burden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153782,"accession_number":"0001641172-25-012791","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma Reports CC-42344 Shows 1,000-fold Greater Potency Than Tamiflu Against H5N1 Avian Flu","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).","The PB2 inhibitor targets a highly conserved active site and has shown favorable safety in a Phase 1 study.","H5N1 has spread in U.S. dairy cattle since March 2024, with rare human cases and low population immunity according to CDC.","Cocrystal plans further clinical evaluation of CC-42344 for pandemic and seasonal influenza treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153781,"accession_number":"0001641172-25-010537","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma Q1 net loss $2.3M, cash $6.9M; CDI-988 shows broad norovirus activity, human challenge planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.","R&D expenses decreased to $1.4M from $3.0M; G&A down to $1.0M from $1.2M.","Unrestricted cash $6.9M at March 31, 2025 vs $9.9M at Dec 31, 2024; working capital $6.9M.","CDI-988 showed superior broad-spectrum antiviral activity against norovirus GII.17 strains; expects to report topline Phase 1 high-dose results in Q2 2025.","Plan to initiate a U.S. human challenge study for CDI-988 as norovirus treatment and prophylaxis in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153780,"accession_number":"0001641172-25-005944","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma's Norovirus Antiviral CDI-988 Shows Potent Activity Against Emerging GII.17 Variants","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.","Company plans to initiate a human norovirus challenge study in 2025 for prevention and treatment.","Phase 1 study showed favorable safety and tolerability of CDI-988 in healthy adults.","Norovirus causes ~685 million cases and ~50,000 child deaths annually with $60B societal cost.","No approved antiviral treatments or vaccines for norovirus exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153779,"accession_number":"0001641172-25-005876","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma furnishes corporate presentation with no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an investor presentation on April 23, 2025 under Item 7.01 Regulation FD.","Presentation content not provided; no specific data on pipeline, finances, or milestones.","No material operational, financial, or strategic updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153778,"accession_number":"0001641172-25-003232","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cocrystal Pharma adopts 2025 Equity Incentive Plan with 1.5M initial shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective March 31, 2025; shareholder approval required under Nasdaq rules.","Initially authorizes 1,500,000 shares of common stock for awards.","Annual increase on Jan 1 each year: 5% of outstanding shares, up to 2,500,000 per year (total cap 4,000,000).","Plan expires March 31, 2035; awards can include options, SARs, restricted stock, RSUs, performance shares/units, cash.","No specific officer/director grants announced; plan is broad-based for employees, consultants, directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153777,"accession_number":"0001641172-25-002088","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cocrystal Pharma files corrected auditor consent referencing S-3 registration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected Weinberg & Company consent for Form S-3 (No. 333-271883) filed as Exhibit 23.1.","Omission of registration statement reference from consent originally filed in 2024 10-K is remedied.","Consent is now incorporated by reference into the Registration Statement.","No new financial or operational information is provided; no changes to prior filings.","Filing is administrative only and does not affect ongoing business or disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172467,"accession_number":"0001641172-25-001494","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.","Cash and equivalents $9.9M as of Dec 31 2024, down from $26.4M a year earlier; working capital $9.2M.","Plans to initiate norovirus human challenge study in U.S. in 2025 for oral pan-viral protease inhibitor CDI-988.","Will continue Phase 2a influenza challenge study of CC-42344 after low infection rate precluded efficacy data.","Expects topline results from CDI-988 high-dose cohort in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172466,"accession_number":"0001493152-25-001870","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma files corporate presentation; no material financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing under Item 7.01 for an investor presentation dated January 13, 2025.","No earnings, clinical data, guidance changes, or other material facts included in the filing or exhibit.","Exhibit 99.1 attached but contains no extractable substantive content in the provided text.","Presentation was made to investment community; specific slide content not available for summary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172465,"accession_number":"0001493152-25-001314","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma reports favorable Phase 1 safety/tolerability for oral antiviral CDI-988 at 800 mg for 10 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.","Pan-viral inhibitor targets norovirus and coronaviruses; no approved antivirals for norovirus exist.","Company plans to start human challenge study in norovirus-infected subjects later in 2025.","Norovirus outbreaks surge in U.S.; CDC estimates 21 million annual U.S. cases and $10.6B economic burden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189465,"accession_number":"0001493152-24-052600","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.","Low infectivity of H3N2 challenge strain made virology data uninterpretable; enrollment to be extended.","Company plans to submit protocol amendment to UK MHRA to extend enrollment and ensure adequate infection rates.","CC-42344 showed favorable safety/tolerability, but low infection rate hindered antiviral data analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189464,"accession_number":"0001493152-24-045083","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.","Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.","R&D expenses $3.2M (down from $4.2M); G&A $1.8M (stable).","Expects topline results from Phase 2a influenza A challenge study (CC-42344) by year end 2024.","Topline results from Phase 1 norovirus/coronavirus study (CDI-988) expected late 2024/early 2025; cash sufficient for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189463,"accession_number":"0001493152-24-043141","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma highlights in vitro activity of CC-42344 against avian H5N1, Phase 2a data expected by end of 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.","Phase 2a human challenge study for seasonal influenza A topline safety/tolerability results expected by end of 2024.","Phase 1 study of pan-viral candidate CDI-988 for noroviruses and coronaviruses; topline data expected late 2024 or early 2025.","No approved vaccine or antiviral for norovirus; estimated 685M cases and 200K deaths annually worldwide (CDC).","Preparations underway for US IND application for late-stage study of CC-42344."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189462,"accession_number":"0001493152-24-040757","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cocrystal Pharma ratifies exec salary hikes to $416K, $200K bonuses, and RSU grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Martin (CFO/co-CEO) and Dr. Sam Lee (President/co-CEO) base salary increased from $400K to $416K, plus $200K bonus and 40,000 RSUs each.","Non-employee director grants: Dr. Kornberg $60.5K cash + $100K SAB stipend + 28,109 RSUs; Dr. Frost $44,770 + 27,100 RSUs; Steven Rubin $82,280 + 18,957 RSUs.","Other director grants: Fred Hassan $36,300 + 8,067 RSUs; Richard Pfenniger $36,300 + 8,067 RSUs; Dr. Japour $54,450 + 14,924 RSUs.","Half of each RSU grant vested immediately; remaining half vests quarterly over two years starting Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205969,"accession_number":"0001493152-24-033220","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.","Expects to report topline results from Phase 1 multiple-ascending cohorts for oral norovirus/coronavirus protease inhibitor CDI-988 in late 2024 or early 2025.","Management will present at Virtual Investor Summit Microcap Forum on Aug 20, 2024, and H.C. Wainwright Conference starting Sept 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205968,"accession_number":"0001493152-24-031886","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.","Cash $18.1M at June 30 from $26.4M at Dec 31; runway expected to fund operations for next 12 months.","Topline results from Phase 2a influenza A human challenge study (oral CC-42344) expected in 2025.","In vitro data shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein recently found in U.S. dairy cows.","Topline Phase 1 results for pan-coronavirus/norovirus oral CDI-988 expected late 2024 / early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205967,"accession_number":"0001493152-24-028283","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.","No serious adverse events, severe TEAEs, or clinically significant lab/ECG findings; all 48 participants completed.","CDI-988 targets a conserved 3CL protease region; potential first dual broad-spectrum treatment for norovirus and coronavirus.","MAD cohort enrollment planned to start in Q4 2024; drug product currently being manufactured.","Norovirus causes ~21M US cases/year; no approved antiviral or vaccine for norovirus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222986,"accession_number":"0001493152-24-025598","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cocrystal Pharma shareholders authorize capital reduction, elect directors, reject officer liability amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reducing authorized capital to 100M common + 1M preferred shares; amendment effective June 27, 2024.","Six directors elected: Roger Kornberg, Phillip Frost, Fred Hassan, Anthony Japour, Richard Pfenniger, Steven Rubin.","Weinberg & Company ratified as independent auditor for fiscal year ending December 31, 2024.","Proposal to limit officer liability failed (4.85M for, 338K against; abstentions 26,484).","Non-binding advisory vote on exec compensation approved; company will hold say-on-pay vote every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222985,"accession_number":"0001493152-24-024430","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.","Phase 2a clinical trial of oral CC-42344 in influenza A subjects ongoing; topline results expected in second half of 2024.","CC-42344 binds to highly conserved PB2 region; high barrier to resistance and broad-spectrum activity highlighted.","CDC reports first human H5N1 cases from dairy cows; company notes no FDA-approved vaccine for humans against this strain.","Positive Phase 1 safety/tolerability data reported in 2022; structure-based platform used to confirm binding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222984,"accession_number":"0001493152-24-018798","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.","R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.","Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.","Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.","Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222983,"accession_number":"0001493152-24-017354","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.","Study evaluating safety, tolerability, antiviral and clinical measurements of CC-42344 for pandemic and seasonal influenza A.","Topline results expected later this year; study conducted in the United Kingdom.","Company also plans to begin Phase 1 study in Australia with inhaled formulation of CC-42344.","Received positive Pre-IND feedback from FDA in March 2024 guiding Phase 2b protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242475,"accession_number":"0001493152-24-011612","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cocrystal Pharma reports FY2023 net loss of $18.0M; pipeline progress on influenza and COVID-19 programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.","Cash at Dec 31, 2023: $26.4M, down from $37.1M; net cash used in ops $14.7M.","FDA provided Pre-IND feedback clarifying requirements for Phase 2b trial of oral CC-42344 for influenza A.","Expect topline data in 2024 from Phase 2a human challenge study with CC-42344 and Phase 1 study with CDI-988.","Plan to initiate Phase 1 study of inhaled CC-42344 in 2024 as influenza treatment/prophylactic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242474,"accession_number":"0001493152-24-010426","cik":1412486,"company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.","Guidance clarifies regulatory requirements for planned Phase 2b trial design.","Phase 2a challenge study in UK ongoing; topline results expected H2 2024.","Preparations underway for inhaled CC-42344 Phase 1 study in Australia.","Inhaled formulation showed superior lung exposure and favorable safety in preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15373009.736607144,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}